Market Overview

Acute Coronary Syndrome Drug Development Pipeline Analysis Report 2018 - ResearchAndMarkets.com

Share:

The "2018
Acute Coronary Syndrome Drug Development Pipeline Analysis Report-
Companies, Drugs, Clinical Trials, Latest Developments in Acute Coronary
Syndrome Market"
report has been added to ResearchAndMarkets.com's
offering.

Worldwide, an estimated 2 to 3 million people are hospitalized due to
ACS annually. The acute coronary syndrome is a common complication of
coronary heart disease. ACS refers to a broad range of diseases
including Unstable angina, Non-ST segment elevation MI, ST-segment
elevation MI. A sudden decrease in blood flow into the heart is
observed, eventually resulting in thrombotic occlusion of a coronary
artery. A sustained block of blood flow to the heart causes the death of
the muscle tissue.

To assist researchers, investors and business development managers, the
publisher has come up with a comprehensive report on Acute Coronary
Syndrome pipeline. The report provides insights into different
therapeutic candidates in preclinical, research, discovery, NDA/IND, pre
registration, phase 1, phase 2, and phase 3 trials. Drugs under
development directly and through combination with other drugs are also
included.

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Acute Coronary Syndrome
pipeline product. Mechanism of Action and the target area of the
pipeline product are also provided.

In addition to complete details of each product, the report provides key
trends in Acute Coronary Syndrome pipeline studies. The products under
development are categorized according to their development phase,
mechanism and company to provide detailed insights into the type of
drugs being developed and the stages of development.

Companies Mentioned

  • Actelion Pharmaceuticals Ltd.
  • advanceCor GmbH
  • Allergan plc
  • Ascendia Pharmaceuticals LLC
  • Bayer AG
  • Cardiome Pharma Corp.
  • Cerenis Therapeutics Holding SA
  • CSL Limited
  • DalCor Pharmaceuticals Canada Inc.
  • PT. Dexa Medica
  • HitGen LTD
  • LipimetiX Development Inc
  • MedImmune LLC
  • Pfizer Inc.
  • Resverlogix Corporation
  • Verseon Corporation

Key Topics Covered:

1 Table of Contents

2 Acute Coronary Syndrome Pipeline Analysis

3 Acute Coronary Syndrome- Company Wise Pipeline Analysis

4 Acute Coronary Syndrome R&D Pipeline Snapshots

5 Recent Developments in Acute Coronary Syndrome Pipeline

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/x39b9v/acute_coronary?w=4

View Comments and Join the Discussion!